Therapeutic strategies for Parkinson’s disease: promising agents in early clinical development

FABBRI, MARGHERITA; PEREZ-LLORET, SANTIAGO; RASCOL, OLIVIER

EXPERT OPINION ON INVESTIGATIONAL DRUGS

INFORMA HEALTHCARE

Año: 2020 vol. 29 p. 1249 - 1267

1354-3784

Introduction: To date, no drug has demonstrated clinically indisputable neuroprotective efficacy in Parkinson?s disease (PD). We also have no effective symptomatic treatment for disabling symptoms such as balance problems, and dementia, and we need to improve the efficacy and safety profile of drugs currently used in the management of motor complications. Areas covered: We examine the agents which appear to have most therapeutic promise based on concepts, feasibility in a reasonable time frame, and available clinical data and place an emphasis on disease-modifying treatments. PUBMED and Clinicaltrials.gov databases were searched for Phase I and II randomized trials for symptomatic or disease-modifying treatments considering only studies that began since 2010 or that were completed after 2015, up to 30 April 2020. Expert opinion: Encouraging progress has been made in our understanding of molecular pathways. We find passive immunization approaches against α-synuclein, LRRK2 kinase inhibitors, and treatment that can increase GCase activity, which have shown some efficacy on both GBA-mutated and non-mutated PD patients. The recognition of non-dopaminergic impairment and the prominent role of non-motor symptoms have prompted the development of trials on compounds that could tackle different neurotransmitter systems. Future approaches will encompass more personalized medicine strategies based on molecular signatures and non-motor phenotypes.